Similar Items: Toxicity outcomes of concurrent radiotherapy with adjuvant capecitabine in triple-negative breast cancer (TROD 06-24)
- The adenosine A receptor in triple-negative breast cancer: molecular mechanisms and therapeutic implications
- Integrated network pharmacology reveal new key curcumin-binding targets in triple-negative breast cancer
- A bibliometric analysis of global research trends in adoptive cell therapy for triple negative breast cancer over the past 15 years
- Evaluating the value of neoadjuvant radiotherapy in patients with breast cancer
- Recognising pituitary and thyroid dysfunction after craniospinal radiotherapy: an underrecognised mixed endocrine toxicity
- Derivation and external validation of a prognostic nomogram for human epidermal growth factor receptor 2 negative early young breast cancer in women